Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis

  • Carla Rognoni
  • Oriana Ciani
  • Silvia Sommariva
  • Irene Bargellini
  • Sherrie Bhoori
  • Roberto Cioni
  • Antonio Facciorusso
  • Rita Golfieri
  • Annagiulia Gramenzi
  • Vincenzo Mazzaferro
  • Cristina Mosconi
  • Francesca Ponziani
  • Rodolfo Sacco
  • Franco Trevisani
  • Rosanna Tarricone
ORKG logo View in ORKG
Publication date
July 2018
Publisher
Springer Science and Business Media LLC
Journal
BMC Cancer

Abstract

Abstract Background Trans-arterial radio-embolization (TARE) is an emerging treatment for the management of hepatocellular carcinoma (HCC). TARE may compete with systemic chemotherapy, sorafenib, in intermediate stage patients with prior chemoembolization failure or advanced patients with tumoral macrovascular invasion with no extra-hepatic spread and good liver function. We performed a budget impact analysis (BIA) evaluating the expected changes in the expenditure for the Italian Healthcare Service within scenarios of increased utilization of TARE in place of sorafenib over the next five years. Methods Starting from patient level data from three oncology centres in Italy, a Markov model was developed to project on a lifetime horizon surviv...

Extracted data

We use cookies to provide a better user experience.